These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 17433961)

  • 1. Visipaque (iodixanol) and hexabrix (ioxaglate) in renal insufficiency.
    Deray G
    J Am Coll Cardiol; 2007 Apr; 49(15):1668. PubMed ID: 17433961
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in coronary angiography.
    Persson P; Liss P; Hansell P
    J Am Coll Cardiol; 2007 Apr; 49(15):1668-1669. PubMed ID: 17433962
    [No Abstract]   [Full Text] [Related]  

  • 3. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial.
    Jo SH; Youn TJ; Koo BK; Park JS; Kang HJ; Cho YS; Chung WY; Joo GW; Chae IH; Choi DJ; Oh BH; Lee MM; Park YB; Kim HS
    J Am Coll Cardiol; 2006 Sep; 48(5):924-30. PubMed ID: 16949481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of iodixanol (Visipaque) and ioxaglate (Hexabrix) in coronary angiography and ventriculography: a double-blind randomized study].
    Roriz R; de Gevigney G; Finet G; Nantois-Collet C; Borch KW; Amiel M; Beaune J
    J Radiol; 1999 Jul; 80(7):727-32. PubMed ID: 10431273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immediate and late adverse reactions in coronary angiography. A comparison between iodixanol and ioxaglate.
    Fransson SG; Stenport G; Andersson M
    Acta Radiol; 1996 Mar; 37(2):218-22. PubMed ID: 8600966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized prospective trial of ioxaglate 320 (Hexabrix) vs. iodixanol 320 (Visipaque) in patients undergoing percutaneous coronary intervention.
    Sutton AG; Ashton VJ; Campbell PG; Price DJ; Hall JA; de Belder MA
    Catheter Cardiovasc Interv; 2002 Nov; 57(3):346-52. PubMed ID: 12410513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One-year results of the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) Study.
    Giustino G; Baber U; Mastoris I; Vlachojannis GJ; Yu J; Teirstein PS; Downey WE; Batchelor WB; Casterella PJ; Nikolsky E; Wong SC; Theodoropoulos KN; Dangas GD; Mehran R
    Catheter Cardiovasc Interv; 2016 Mar; 87(4):703-9. PubMed ID: 26481591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iodixanol in cardioangiography. A double-blind parallel comparison between iodixanol 320 mg I/ml and ioxaglate 320 mg I/ml.
    Tveit K; Bolz KD; Bolstad B; Haugland T; Berg KJ; Skjaerpe T; Kloster YF
    Acta Radiol; 1994 Nov; 35(6):614-8. PubMed ID: 7946687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal failure in 57 925 patients undergoing coronary procedures using iso-osmolar or low-osmolar contrast media.
    Liss P; Persson PB; Hansell P; Lagerqvist B
    Kidney Int; 2006 Nov; 70(10):1811-7. PubMed ID: 17003814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iodixanol vs ioxaglate for preventing contrast nephropathy: who is winner?
    Jo SH; Koo BK; Youn TJ; Kim HS
    Kidney Int; 2007 Apr; 71(8):828; author reply 828-9. PubMed ID: 17429424
    [No Abstract]   [Full Text] [Related]  

  • 11. Ionic low-osmolar versus nonionic iso-osmolar contrast media to obviate worsening nephropathy after angioplasty in chronic renal failure patients: the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) study.
    Mehran R; Nikolsky E; Kirtane AJ; Caixeta A; Wong SC; Teirstein PS; Downey WE; Batchelor WB; Casterella PJ; Kim YH; Fahy M; Dangas GD
    JACC Cardiovasc Interv; 2009 May; 2(5):415-21. PubMed ID: 19463464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of anticoagulation on ionic and nonionic contrast media effect on thrombogenesis and fibrinolysis: The PEPCIT study.
    Bellemain-Appaix A; Beygui F; Lesty C; Gupta S; Silvain J; Le Feuvre C; Cayla G; Allali Y; Montalescot G; Collet JP
    Catheter Cardiovasc Interv; 2012 Apr; 79(5):823-33. PubMed ID: 21618678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nephrotoxicity of iodixanol versus ioversol in patients with chronic kidney disease: the Visipaque Angiography/Interventions with Laboratory Outcomes in Renal Insufficiency (VALOR) Trial.
    Rudnick MR; Davidson C; Laskey W; Stafford JL; Sherwin PF;
    Am Heart J; 2008 Oct; 156(4):776-82. PubMed ID: 18946896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Major Adverse Renal and Cardiac Events After Coronary Angiography and Cardiac Surgery.
    Tecson KM; Brown D; Choi JW; Feghali G; Gonzalez-Stawinski GV; Hamman BL; Hebeler R; Lander SR; Lima B; Potluri S; Schussler JM; Stoler RC; Velasco C; McCullough PA
    Ann Thorac Surg; 2018 Jun; 105(6):1724-1730. PubMed ID: 29408241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relative renal safety of iodixanol compared with low-osmolar contrast media: a meta-analysis of randomized controlled trials.
    Reed M; Meier P; Tamhane UU; Welch KB; Moscucci M; Gurm HS
    JACC Cardiovasc Interv; 2009 Jul; 2(7):645-54. PubMed ID: 19628188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial of contrast media utilization in high-risk PTCA: the COURT trial.
    Davidson CJ; Laskey WK; Hermiller JB; Harrison JK; Matthai W; Vlietstra RE; Brinker JA; Kereiakes DJ; Muhlestein JB; Lansky A; Popma JJ; Buchbinder M; Hirshfeld JW
    Circulation; 2000 May; 101(18):2172-7. PubMed ID: 10801758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of a nonionic, iso-osmolar contrast medium (iodixanol) versus an ionic, low-osmolar contrast medium (ioxaglate) on major adverse cardiac events in patients undergoing percutaneous transluminal coronary angioplasty: A multicenter, randomized, double-blind study. Visipaque in Percutaneous Transluminal Coronary Angioplasty [VIP] Trial Investigators.
    Bertrand ME; Esplugas E; Piessens J; Rasch W
    Circulation; 2000 Jan; 101(2):131-6. PubMed ID: 10637198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiocontrast-induced nephropathy.
    Carver JR
    J Invasive Cardiol; 2003 Jun; 15(6):315-6. PubMed ID: 12777668
    [No Abstract]   [Full Text] [Related]  

  • 19. A prospective, double-blind, randomized, controlled trial on the efficacy and cardiorenal safety of iodixanol vs. iopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention.
    Nie B; Cheng WJ; Li YF; Cao Z; Yang Q; Zhao YX; Guo YH; Zhou YJ
    Catheter Cardiovasc Interv; 2008 Dec; 72(7):958-65. PubMed ID: 19021282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prevention of contrast-induced nephropathy by simultaneous hemofiltration during coronary angiographic procedures: a comparison with periprocedural hemofiltration.
    Choi MJ; Yoon JW; Han SJ; Choi HH; Song YR; Kim SG; Oh JE; Lee YK; Seo JW; Kim HJ; Noh JW; Koo JR
    Int J Cardiol; 2014 Oct; 176(3):941-5. PubMed ID: 25200848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.